FINAL ANALYSIS OF AN OBSERVATIONAL PROSPECTIVE STUDY DESCRIBING BRENTUXIMAB VEDOTIN USE IN ROUTINE PRACTICE IN FRANCE FOR HODGKIN LYMPHOMA AND NON-HODGKIN LYMPHOMA.
Author(s): ,
DAVID SIBON
Affiliations:
Hematology,Necker University Hospital,Paris,France
,
PHILIPPE QUITTET
Affiliations:
Hematology,CHU Montpellier,Montpellier,France
,
CECILE BOREL
Affiliations:
Hematology,IUCT-ONCOPOLE,Toulouse,France
,
MOHAMMAD HAMMOUD
Affiliations:
Hematology,Mondor University Hospital,Créteil,France
,
REMY DULERY
Affiliations:
Hematology,Saint-Antoine University Hospital,Paris,France
,
SOPHIE DE GUIBERT
Affiliations:
Hematology,CHU Rennes,Rennes,France
,
ASPASIA STAMATOULLAS
Affiliations:
Hematology,Centre Henri Becquerel,Rouen,France
,
OMAR BENBRAHIM
Affiliations:
Hematology,CHR Orléans,Orléans,France
,
HERVE GHESQUIERES
Affiliations:
Hematology,CH Lyon-Sud,Pierre-Bénite,France
,
PATRICIA FRANCHI REZGUI
Affiliations:
Hematology,Cochin University Hospital,Paris,France
,
QUOC HUNG LE
Affiliations:
Hematology,CHU Reims,Reims,France
,
COLOMBE COULIBALY
Affiliations:
TAKEDA France,Puteaux,France
,
OLIVIER CASASNOVAS
Affiliations:
Hematology,CHU Dijon,Dijon,France
,
REDA BOUABDALLAH
Affiliations:
Hematology,IPC,Marseille,France
PAULINE BRICE
Affiliations:
Hematology,Saint-Louis University Hospital,Paris,France
(Abstract release date: 05/14/20) EHA Library. SIBON D. 06/12/20; 293642; EP1153
DAVID SIBON
DAVID SIBON
Contributions
Abstract

Abstract: EP1153

Type: e-Poster

Background

Use of brentuximab vedotin (BV) in clinical practice has not been widely described as in clinical trial. 

Aims
To report the use of BV in HL patients ≥ 60 years old and NHL patients in clinical practice.

Methods
ODICE is a national observational prospective study designed to evaluate the use of BV for the treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) in routine practice. Patients receiving BV were registered in annual independent cohorts from January 2015 to December 2018 at participating centers. We report here the pooled results of the 2015, 2016, 2017 and 2018 cohorts. The primary objective was to describe the use of BV therapy outside of clinical trials; Secondary objectives were to report response rate, survival and safety in real life. Here we report the results in HL patients ≥ 60 years old and NHL patients.

Results

47 sites registered 501 patients of which 493 were evaluable. 335 patients (68%) were treated for HL (92 of whom were ≥ 60 years old) and 158 (32 %) for NHL.

For the 92 (27 %) HL patients ≥ 60 years old, the median number of previous treatments before BV was 2 (range 0-5). Thirty-five (38%) patients received BV in 2nd line, 37 (40%) in 3rd line and 13 (14%) beyond the 3rd line; 7 (8%) patients received BV in first-line treatment. Previous treatments before BV initiation included chemotherapy in 84 patients and radiotherapy in 14 patients. Nine patients (10%) had previously undergone stem-cell transplantation, mainly autologous (ASCT, 89%). At BV initiation, Ann Arbor stage was III-IV in 80%; performance status was 0-1 in 62%; and B symptoms were present in 31%. BV was used as monotherapy in 40% of HL patients or in combination with chemotherapy in 60% (mainly bendamustine or gemcitabine) and the median number of BV cycles was 6. After BV treatment, 10 patients underwent ASCT. 19% of patients discontinued BV for adverse events. Survival will be presented at the congress.

The 158 patients with NHL were diagnosed with peripheral T-cell lymphoma (PTCL; 41 systemic ALCL, 38 PTCL-NOS, 28 AITL, 7 ATLL, 4 EATL, 3 ENKTL, and 3 others), cutaneous T-cell lymphoma (17) or B-NHL (14 DLBCL, 3 PMBL). At BV initiation, Ann Arbor stage was III-IV in 85% of cases, ECOG was 0-1 in 86% of cases, and extranodal involvement was present in 50%. Before BV initiation, patients had received a median of 2 previous lines of treatment including chemotherapy (87%) and stem-cell transplantation (15%). BV was used as a bridge to transplantation in 74 patients (47%) and for consolidation after ASCT in 12 patients. Survival will be presented at the congress.

Conclusion
In HL patients ≥ 60 years old, BV was mainly prescribed after a median of 2 previous lines of treatment, in association with chemotherapy for a median of 6 cycles. In NHL patients, BV was mainly prescribed in PTCL after a median of 2 previous lines of treatment, in association with chemotherapy, and as a bridge to transplantation for about half of the patients.

Session topic: 17. Hodgkin lymphoma - Clinical

Keyword(s): Elderly, Hodgkin's lymphoma, Peripheral T-cell lymphoma, Treatment

Abstract: EP1153

Type: e-Poster

Background

Use of brentuximab vedotin (BV) in clinical practice has not been widely described as in clinical trial. 

Aims
To report the use of BV in HL patients ≥ 60 years old and NHL patients in clinical practice.

Methods
ODICE is a national observational prospective study designed to evaluate the use of BV for the treatment of Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL) in routine practice. Patients receiving BV were registered in annual independent cohorts from January 2015 to December 2018 at participating centers. We report here the pooled results of the 2015, 2016, 2017 and 2018 cohorts. The primary objective was to describe the use of BV therapy outside of clinical trials; Secondary objectives were to report response rate, survival and safety in real life. Here we report the results in HL patients ≥ 60 years old and NHL patients.

Results

47 sites registered 501 patients of which 493 were evaluable. 335 patients (68%) were treated for HL (92 of whom were ≥ 60 years old) and 158 (32 %) for NHL.

For the 92 (27 %) HL patients ≥ 60 years old, the median number of previous treatments before BV was 2 (range 0-5). Thirty-five (38%) patients received BV in 2nd line, 37 (40%) in 3rd line and 13 (14%) beyond the 3rd line; 7 (8%) patients received BV in first-line treatment. Previous treatments before BV initiation included chemotherapy in 84 patients and radiotherapy in 14 patients. Nine patients (10%) had previously undergone stem-cell transplantation, mainly autologous (ASCT, 89%). At BV initiation, Ann Arbor stage was III-IV in 80%; performance status was 0-1 in 62%; and B symptoms were present in 31%. BV was used as monotherapy in 40% of HL patients or in combination with chemotherapy in 60% (mainly bendamustine or gemcitabine) and the median number of BV cycles was 6. After BV treatment, 10 patients underwent ASCT. 19% of patients discontinued BV for adverse events. Survival will be presented at the congress.

The 158 patients with NHL were diagnosed with peripheral T-cell lymphoma (PTCL; 41 systemic ALCL, 38 PTCL-NOS, 28 AITL, 7 ATLL, 4 EATL, 3 ENKTL, and 3 others), cutaneous T-cell lymphoma (17) or B-NHL (14 DLBCL, 3 PMBL). At BV initiation, Ann Arbor stage was III-IV in 85% of cases, ECOG was 0-1 in 86% of cases, and extranodal involvement was present in 50%. Before BV initiation, patients had received a median of 2 previous lines of treatment including chemotherapy (87%) and stem-cell transplantation (15%). BV was used as a bridge to transplantation in 74 patients (47%) and for consolidation after ASCT in 12 patients. Survival will be presented at the congress.

Conclusion
In HL patients ≥ 60 years old, BV was mainly prescribed after a median of 2 previous lines of treatment, in association with chemotherapy for a median of 6 cycles. In NHL patients, BV was mainly prescribed in PTCL after a median of 2 previous lines of treatment, in association with chemotherapy, and as a bridge to transplantation for about half of the patients.

Session topic: 17. Hodgkin lymphoma - Clinical

Keyword(s): Elderly, Hodgkin's lymphoma, Peripheral T-cell lymphoma, Treatment

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies